- Home
- SLRX
as 07-26-2024 4:00pm EST
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 1.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 6.0M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -19.92 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.35 - $7.92 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Salarius Pharmaceuticals Inc. News
SLRX Breaking Stock News: Dive into SLRX Ticker-Specific Updates for Smart Investing
MT Newswires
15 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
MT Newswires
15 days ago
Sector Update: Health Care Stocks Advance in Afternoon Trading
MT Newswires
15 days ago
Top Midday Decliners
MT Newswires
15 days ago
Salarius Pharmaceuticals Says FDA Placed Cancer Treatment Trial on Partial Hold; Shares Fall
GlobeNewswire
a month ago
Clinical Data on Salarius Pharmaceuticals’ Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting
GlobeNewswire
a month ago
Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split
The Telegraph
2 months ago
Italian energy company targets Britain for fleet of 20 mini-nukes
Motley Fool
2 months ago
4 Reasons to Buy Invesco QQQ Trust Like There's No Tomorrow
Compare SLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRX Salarius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.